|Bid||6.89 x 4000|
|Ask||7.20 x 2900|
|Day's Range||6.84 - 7.11|
|52 Week Range||4.50 - 9.11|
|Beta (3Y Monthly)||1.71|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Medical marijuana and recreational marijuana are two high growth sectors in the cannabis industry. Learn about how the two differ, and how you can get into the market.
The cannabis industry has grown in recent months and years, and many companies in the cannabis and health-related industries have been uplisted to reputable U.S. exchanges. Learn about the marijuana stocks on the Nasdaq.
Yuval Cohen became the CEO of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) in 2014. First, this article will...
The clinical-stage biotech's top- and bottom-line numbers weren't the most important thing in the first quarter.
Corbus Pharmaceuticals (CRBP) delivered earnings and revenue surprises of -2250.00% and -91.01%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
The Norwood, Massachusetts-based company said it had a loss of 43 cents per share. The results did not meet Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment ...
Corbus Pharmaceuticals (CRBP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zynerba Pharmaceuticals' (ZYNE) operating expenses are expected to be higher in the first quarter due to clinical studies on its lead pipeline candidate, Zygel.
Cannabis and marijuana stocks are an exciting industry right now. According to Cowen & Co.'s Vivien Azer - a pioneer in cannabis-stock analysis - U.S. marijuana sales are set to reach about $80 billion by 2030. Currently, U.S. legal and illicit sales combined total at least $50 billion. That's on top of an estimated $C12 billion in Canadian revenue by 2025 for both recreational and medical use.The problem? It's still early days for the sector, which means significant risk is involved. It's common to see these primarily small- and mid-cap stocks move 10% or more in response to headlines or quarterly earnings reports. Companies are rushing to establish an early leadership position, and not all of them will end up winners. Plus, the federal legalization of cannabis in the U.S. remains a big question mark.So how do you pinpoint the most compelling investing opportunities in this lucrative industry? One option is to focus on the cannabis stocks that the Street is most bullish on right now.We used TipRanks market data to pinpoint five cannabis and marijuana stocks to buy based on overwhelmingly positive consensus ratings among Wall Street analysts. Let's take a closer look at each. SEE ALSO: Goldman Sachs: 7 Growth Stocks to Buy With Explosive Potential
Corbus Pharmaceuticals (CRBP) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Payroll numbers were nicely ahead of estimates and the unemployment rate was around a 50 year low. This data undermines arguments about a slowing economy but it causes the bears to wonder if things are so great then why is it still expected that the Fed will cut rates later this year? Isn't it inconsistent for the Fed to be so dovish when the economic news looks so good?
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put in...
Corbus Pharmaceuticals (CRBP) closed the most recent trading day at $7.23, moving -1.23% from the previous trading session.
Corbus Pharmaceuticals (CRBP) closed at $7.18 in the latest trading session, marking a -0.97% move from the prior day.
What to Expect from Charlotte’s Web Holdings' Q4 EarningsCharlotte’s Web Holdings Charlotte’s Web Holdings (CWBHF) is scheduled to release its fourth-quarter earnings on March 28 after markets close. The company plans to hold its earnings call